Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 519 of 5804
-
New drug combo aims to outsmart Hard-to-Treat cancers
Disease control OngoingThis phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (adva…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could common drugs help heal traumatic brain injuries? new trial aims to find out
Disease control ENROLLING_BY_INVITATIONThe purpose of this study is to determine if experimental drug treatment improves recovery after TBI as compared to a control (placebo) group. Changes in recovery will be measured throughout the study. The study drugs listed below are approved by the U.S. Food and Drug Administra…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Recruiting nowThe goal of this Phase I/II, single arm, prospective, open label, dose escalation trial is to assess safety, feasibility and efficacy of ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR) specific for dNPM1 peptides restricted to human leu…
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
MRI-Guided radiation could sharpen lung cancer treatment
Disease control Recruiting nowThis study is a randomized phase III trial that aiming to investigate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) guided hypofractionated radiotherapy (hypo-RT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who are planned …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New triple therapy aims to slow advanced lung cancer
Disease control Recruiting nowThis study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.
Phase: PHASE2 • Sponsor: Second Hospital of Shanxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Simple blood, breath, and stool tests could revolutionize colon cancer screening
Diagnosis Recruiting nowThe primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection. These CRC screening technologies would be low cost, breakthrough and of high sensitivity and specificity.
Sponsor: Firalis SA • Aim: Diagnosis
Last updated Jun 26, 2026 16:38 UTC
-
Immunotherapy combo shows promise against tough rectal cancers
Disease control Recruiting nowColorectal cancer is a common gastrointestinal tumor, with rising incidence in China. Rectal cancer accounts for nearly half of new cases, and many patients are diagnosed at a locally advanced stage. Neoadjuvant chemoradiotherapy (nCRT) is the standard treatment, but only 20-30% …
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 26, 2026 13:43 UTC
-
New hope for liver cancer: drug combo targets tough cases
Disease control Recruiting nowThe purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 / PD-L1 immune checkpoint inhibito…
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for Hard-to-Treat lung cancer: drug cocktail targets resistant tumors
Disease control Recruiting nowThis phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) to an anti-PD1 treatment and may have spread from where it first started to near…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New gel could shrink rare skin bumps in kids and adults
Disease control OngoingSELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess the change in microcystic lymphatic malformations…
Phase: PHASE3 • Sponsor: Palvella Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
AI spots hidden heart risks in routine scans, could save thousands from heart attacks
Prevention Recruiting nowAI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-bas…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
New hope for rare eye disease: drug trial targets vision loss
Disease control OngoingThe goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
Phase: PHASE2, PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on lupus and scleroderma
Disease control Recruiting nowThe goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to p…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New pill could ease daily struggles of myasthenia gravis
Disease control Recruiting nowThe study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New heart pump could be safer for High-Risk patients
Disease control OngoingSAVE-PCI is a prospective, multi-center, randomized controlled trial evaluating the safety and efficacy of NyokAssist™, a small-bore percutaneous ventricular assist device (pVAD), in comparison with intra-aortic balloon pump (IABP) in patients undergoing elective high-risk percut…
Phase: NA • Sponsor: magAssist, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug aims to control angelman syndrome long-term
Disease control ENROLLING_BY_INVITATIONThe primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New shot shows promise for tough psoriasis cases
Disease control CompletedThe goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with moderate to severe plaque psoriasis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat plaque psoriasis.
Phase: PHASE3 • Sponsor: SPH-BIOCAD (HK) Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New eye injection aims to stop vision loss in dry AMD patients
Disease control OngoingThe primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New breast cancer trial aims to wipe out tumors before surgery
Disease control Recruiting nowRandomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.
Phase: PHASE2 • Sponsor: Nagoya City University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Glow-and-Kill surgery: new light therapy targets hidden cancer cells
Disease control Recruiting now\*As of June 2026- Phase I has been completed and we are now in Phase II. This phase I/II trial studies the side effects and how well fluorescence image guided surgery followed by intraoperative photodynamic therapy for improving local tumor control in patients with colorectal ca…
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC